CAG
PRME icon

Crestwood Advisors Group’s Prime Medicine PRME Stock Holding History

Crestwood Advisors Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$113K Buy
32,374
+401
+1% +$1.53K ﹤0.01% 756
2025
Q4 		$111K Buy
31,973
+286
+0.9% +$1.27K ﹤0.01% 686
2025
Q3 		$176K Hold
31,687
– – ﹤0.01% 559
2025
Q2 		$78.3K Hold
31,687
– – ﹤0.01% 526
2025
Q1 		$63.1K Hold
31,687
– – ﹤0.01% 494
2024
Q4 		$92.5K Buy
+31,687
New +$111K ﹤0.01% 454

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Crestwood Advisors Group's PRME Position: Q1 2026 in Review

Crestwood Advisors Group increased its Prime Medicine (PRME) stake by 1.3% in Q1 2026, buying an estimated $1.53K and bringing the position to 32,374 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #756.

Crestwood Advisors Group first reported a position in PRME in Q4 2024 and has held it in 6 quarters since. The position peaked at $176K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Crestwood Advisors Group held 32,374 shares of Prime Medicine worth $113K as of Q1 2026.
  • Crestwood Advisors Group bought 401 Prime Medicine shares in Q1 2026, an estimated $1.53K.
  • Prime Medicine made up ﹤0.01% of Crestwood Advisors Group's portfolio in Q1 2026, its #756 holding.
  • Crestwood Advisors Group first reported a position in Prime Medicine in Q4 2024 and has held it in 6 quarters since.
  • Crestwood Advisors Group's Prime Medicine position peaked at $176K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Crestwood Advisors Group's 13F filing for Q1 2026, filed 5 May 2026.